Table 2.
Ongoing clinical trials of oncolytic viruses for thoracic cancers.
| Oncolytic Virus | Disease | Other Therapeutic Agents Involved | Status of Trial | Phase | ClinicalTrials.gov Number |
|---|---|---|---|---|---|
| Adenovirus Vaccine Expressing MAGE-A3 with Genetically-Modified MAGE-A3-Expressing MG1 Maraba Virus Vaccine | Metastatic/Advanced Non-Small Cell Lung Cancer | Pembrolizumab | Not Yet Recruiting | I/II | NCT02879760 |
| Group B Oncolytic Adenovirus (ColoAd1) | Non-Small Cell Lung Cancer | N/A (patients must be candidates for surgery) | Completed | I | NCT02053220 |
| Wild-Type Reovirus | Non-Small Cell Lung Cancer (must have KRAS or EGFR activation) | Carboplatin and Paclitaxel | Completed—Preliminary data indicates greatly increased median survival for patients with EGFR activation | II | NCT00861627 [13] |
| Thymidine Kinase-Deleted Vaccinia Virus | Metastatic/Advanced Non-Small Cell Lung Cancer | GM-CSF | Completed | I | NCT00625456 |
| Measles Virus Vaccine Encoding Thyroidal Sodium Iodide Symporter | Malignant Pleural Mesothelioma | N/A | Recruiting | I | NCT01503177 |
| Cocksackie A21 Virus | Non-Small Cell Lung Cancer | Pembrolizumab | Not Yet Recruiting | Ib | NCT02824965 |
| Seneca Valley Virus (SVV-001) | Small Cell Lung Cancer | N/A | Completed—Negative trial | II | NCT01017601 |
| Herpes Simplex Virus Type 1 (HSV-1716) | Malignant Pleural Mesothelioma | N/A | Active, Not Recruiting | I/II | NCT01721018 |
| GL-ONC1 (Vaccinia Virus Strain) | Malignant Pleural Mesothelioma | - | Recruiting | Ib | NCT01766739 |